A. Lima

发表

Anti‐VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models

I. Kasman, A. Jubb, Mallika Singh, 2012, The Journal of pathology.

Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models

Mallika Singh, W. Forrest, H. Koeppen, 2010, Nature Biotechnology.

EHMT2 methyltransferase governs cell identity in the lung and is required for KRAS G12D tumor development and propagation

A. Daemen, Z. Modrušan, C. Poon, 2020, bioRxiv.

Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy.

P. Hegde, I. Kasman, A. Jubb, 2013, The Journal of clinical investigation.

SEMMs: Somatically Engineered Mouse Models. A New Tool for In Vivo Disease Modeling for Basic and Translational Research

D. Maddalo, A. Lima, 2021, Frontiers in Oncology.

Automated segmentation of lungs and lung tumors in mouse micro-CT scans

M. Junttila, G. Ferl, J. Long, 2022, iScience.

Quantification of Tumor Burden in a Genetically Engineered Mouse Model of Lung Cancer by Micro-CT and Automated Analysis1

R. Carano, L. Johnson, M. Junttila, 2015, Translational oncology.

ERBB signalling contributes to immune evasion in KRAS-driven lung adenocarcinoma

Simak Ali, M. Periyasamy, J. L. Quesne, 2023, bioRxiv.

Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy.

P. Hegde, I. Kasman, A. Jubb, 2013, The Journal of clinical investigation.

Abstract 3295: Inhibiting vascular morphogenesis in tumors: EGFL7 as a novel therapeutic target

I. Kasman, Mallika Singh, R. Carano, 2011 .